Regulation (EU) 2022/1531 – OMNIBUS ACT V – applicable as of 17 December 2022

Date of publication: 15/09/2022

Date of application: 17/12/2022

The European Commission has published the Commission Regulation (EU) 2022/1531, which amends the Regulation (EC) No 1223/2009 as regards the use in cosmetic products of certain substances classified as CMR, by adding new entries to Annex II and Annex III and revising an entry in Annex V.
Liliana Teles

Liliana Teles

Regulatory Affairs Manager


Regulation (EC) No 1272/2008, commonly known as CLP Regulation, provides for a harmonized classification of substances as carcinogenic, mutagenic or toxic for reproduction (CMR) based on an opinion prepared by the Committee for Risk Assessment of the European Chemicals Agency (ECHA). Depending on the level of evidence of their CMR properties, substances are classified as CMR substances of category 1A, 1B or category 2. 

By default, the use of substances classified as CMR under the CLP Regulation is banned according to Article 15 of the European Cosmetics Regulation (EC) No. 1223/2009. Nevertheless, a CMR substance may be used in cosmetic products, by way of exception, if specific conditions are fulfilled. 

With the aim of implementing the prohibition of CMR substances, ensure legal compliance (particularly for economic operators and national competent authorities) and to ensure a high level of protection of human health, these compounds are included in Annex II (List of Substances Prohibited in Cosmetics Products) or Annex III (List of Substances Which Cosmetic Products Must Not Contain Except Subject to the Restrictions Laid Down) of the European Cosmetics Regulation. A CMR substance may also be deleted from Annexes III to VI of the Regulation for these purposes. 


The European Commission has published the Commission Regulation (EU) 2022/1531, which amends the Regulation (EC) No 1223/2009 as regards the use in cosmetic products of certain substances classified as CMR, by adding new entries to Annex II and Annex III and revising an entry in Annex V. 

To Annex II (List of Substances Prohibited in Cosmetic Products), this Commission Regulation adds 14 new substances. For example, Methylene di-t-butylcresol/[DBMC] (CAS number: 119-47-1) and MIBK (CAS number: 108-10-1) are now prohibited in cosmetic products.  

The substance Sodium Hydroxymethylglycinate (CAS number: 70161-44-3) was classified as carcinogenic of category 1B and mutagenic of category 2 by the Commission Delegated Regulation (EU) 2020/1182, and included in Annex VI of the CLP Regulation (Harmonised Classification and Labelling for Certain Hazardous Substances). Sodium Hydroxymethylglycinate is included in Annex V (List of Preservatives Allowed in Cosmetic Products, entry 51) of the European Cosmetics Regulation and may be used up to a maximum concentration of 0.5% in the finished product. However, this ingredient shall not be used in cosmetic products unless it can be shown that the maximum theoretical concentration of releasable formaldehyde (irrespective of the source) in the mixture as placed on the market is <0.1% w/w (see previous publication). Previously, this substance was erroneously included in Annex II (List of Substances Prohibited in Cosmetic Products). The wording of this condition was adapted by the Commission Regulation (EU) 2022/1531 to correctly reflect the prohibition of the substance in cosmetic products. As a substance should not be listed in both Annex II and Annex V, the European Commission deleted this substance from Annex II (entry 1669). 

Methyl Salicylate (CAS number: 119-36-8) is the ester of methyl alcohol and salicylic acid and is used, in cosmetics and personal care products, as a denaturant, flavouring, oral care, perfuming and soothing agent. This substance was classified as toxic for reproduction (CMR substance, category 2) under the CLP Regulation, but, until now, it was not included in the Annexes to Regulation (EC) No 1223/2009. In October 2021, the Scientific Committee on Consumer Safety (SCCS) issued its final opinion on Methyl Salicylate. The Committee concluded that Methyl Salicylate is considered safe when used in cosmetics up to the maximum concentration provided in the dossier submitted (see previous post). Considering its classification as a CMR substance of category 2 and the SCCS opinion, the European Commission concluded that Methyl Salicylate should be added to the List of Substances Restricted in Cosmetic Products (Annex III to Regulation, entry 324), in accordance with the following table: 

Table 1 – Restrictions applied to the use of Methyl Salicylate in cosmetic products. 

Product type, Body partsMaximum concentration in ready for use preparation
a) Leave-on skin products (except face makeup, spray/aerosol body lotion, spray/aerosol deodorant and hydroalcoholic-based fragrances) and leave on hair products (except spray/aerosol) 0,06%
b) Face makeup (except lip products, eye makeup and makeup remover 0,05%
c) Eye makeup and makeup remover 0,002%
d) Leave-on hair products (spray/aerosol) 0,009%
e) Deodorant spray/aerosol 0,009%
f) Body lotion spray/aerosol 0,04% 
g) Rinse-off skin products (except hand wash) and rinse-off hair products 0,06% 
h) Hand wash0,6%
i) Hydroalcoholic-based fragrances 0,6%
j) Lip products 00,03%
k) Toothpaste 2,52%
l) Mouthwash intended for children aged 6–10 years 0,1%
m) Mouthwash intended for children above 10 years of age and adults 0,6%
n) Mouth spray 0,65%

The amendments to the European Cosmetic Regulation are applicable from 17 December 2022 onwards. Products must be compliant from this date.


1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.

2. Regulation (EU) 2022/1531 adding new entries to Annex II and Annex III and revising an entry in Annex V of Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products.


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »